Sandoz is a division of the Novartis Group and a global leader in generic pharmaceuticals and biosimilars and was established in 2003, when Novartis united all of its generics businesses under the name Sandoz – a single global brand with a long history. Since then, Sandoz has grown into a leading global generics business with annual sales of approximately US$10 billion. In her current role, Keren leads Sandoz’ largest commercial and country organization – the United States – which is responsible for over 35% of Sandoz global revenue. She also oversees Sandoz commercial operations in Canada. In addition to serving on the Novartis Country Leadership Team, Keren is a member of the Global Sandoz Executive Committee. Prior to joining Sandoz, Keren served as Global Head of M&A at Novartis International AG. Her early career began at Teva Pharmaceutical Industries where she steadily advanced in leadership roles to Senior VP, Global Business Development and Alliance Management. Keren is a value creator in the biopharmaceutical space, and brings close to 20 years of experience in the pharmaceutical industry, marked by success leading major M&A deals, enterprise innovations, and complex market strategies for large-scale, sustainable growth. Keren holds an MBA in Finance from Bar Ilan University and a Bachelor’s degrees in Economics and Chemistry from Tel Aviv University. Nominated for Top 40 Under 40 in The Marker magazine, she exemplifies the insight and wisdom needed to move global organizations forward. Outside of work, Keren enjoys spending time with her 5 children. She is an avid runner with one marathon and 3 half-marathons under her belt.